Aztreonam Lysine for Inhalation (AZLI)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Complication of Transplanted Lung
Conditions
Complication of Transplanted Lung
Trial Timeline
Mar 1, 2013 → Apr 1, 2015
NCT ID
NCT01469364About Aztreonam Lysine for Inhalation (AZLI)
Aztreonam Lysine for Inhalation (AZLI) is a approved stage product being developed by Gilead Sciences for Complication of Transplanted Lung. The current trial status is completed. This product is registered under clinical trial identifier NCT01469364. Target conditions include Complication of Transplanted Lung.
What happened to similar drugs?
12 of 16 similar drugs in Complication of Transplanted Lung were approved
Approved (12) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01469364 | Approved | Completed |
Competing Products
20 competing products in Complication of Transplanted Lung